Hillhouse led $160m Series B round for Genor Biopharma.

Hillhouse led $160m Series B round for Genor Biopharma, a biopharmaceutical company, which develops and commercializes therapeutic monoclonal antibodies, Fc-fusion proteins, and recombinant therapeutic proteins. The round saw participation from Temasek and Life Science Fund, Kaiyuan International and Cavenham PE. "The year of 2020 is a significant year for Genor Biopharma. we are in the final sprint to push those mature medicines to hit the market, meanwhile accelerating the R&D process in oncological immunotherapy," Guo Feng, Genor CEO.